Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a randomized, observer-blinded, Phase 1/2 study evaluating the safety and immunogenicity of a quadrivalent HA nanoparticle influenza and SARS-CoV-2 rS nanoparticle combination vaccine with Matrix-M1 adjuvant; this combination is referred to as ICC vaccine.
This is a randomized, observer-blinded, Phase 1/2 study evaluating the safety and immunogenicity of a quadrivalent hemagglutinin (HA) nanoparticle influenza vaccine (qNIV) and severe acute respiratory syndrome coronavirus 2 (SARSCoV2) recombinant spike (rS) nanoparticle combination vaccine with Matrix-M1â„¢ adjuvant; this combination vaccine is referred to as Influenza COVID-19 Combination (ICC) vaccine.
The study will enroll approximately 640 healthy (based on history and physical examination) adult male and female participants 50 to 70 years of age, inclusive, targeting participants who are baseline seropositive (either previously infected with SARS-CoV-2 ≥ 8 weeks prior to enrollment, or have been previously immunized against SARS-CoV-2 with a completed regimen of an authorized vaccine at ≥ 8 weeks prior to enrollment). Randomization will be stratified on age ≥ 50 to ≤60 or
≥ 60 to ≤ 70 years to distribute the proportions of each age stratum evenly across vaccine groups.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A and Group C - ICC Vaccine Formulation | Experimental | 2 doses of Formulation 1. 1 dose each on Days 0 and Day 56. |
|
| Group B -ICC Vaccine Formulation | Experimental | 2 doses of Formulation 2. 1 dose each on Days 0 and Day 56. |
|
| Group D - ICC Vaccine Formulation | Experimental | 2 doses of Formulation 3. 1 dose each on Days 0 and Day 56. |
|
| Group E - ICC Vaccine Formulation | Experimental | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. |
|
| Group F- ICC Vaccine Formulation | Experimental | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. |
|
| Group G- ICC Vaccine Formulation | Experimental |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ICC Vaccine | Biological | Intramuscular (deltoid) injections of in-clinic mix of various doses of quadrivalent hemagglutinin nanoparticle influenza vaccine(qNIV2), SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Solicited Local and Systemic Adverse Events (AE's) | Numbers of participants with solicited local and systemic AEs over the 7 days post-injection after first and second doses. | Day 0 to Day 63 |
| Number of Participants Reporting All AE's | Number of participants reporting all AEs, (solicited and unsolicited), over 70 days after the first dose. | Day 0 to Day 70 |
| Number of Participants With MAAEs, AESIs (Including PIMMCs), SAEs | Number of participants with Medical Attended Adverse Events (MAAE's), Adverse events (AESI's), Including potential immune-mediated medical conditions (PIMMCs), Serious Adverse Events SAEs. | Day 0 to Day 180 |
| Measure | Description | Time Frame |
|---|---|---|
| Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the Hemagglutinin (HA) Receptor Binding Domains of Vaccine Homologous Influenza A/Brisbane (H1N1 Subtype) Strain Expressed as Geometric Mean Titers (GMTs) | Hemagglutination-inhibition (HAI) antibody titers specific for the hemagglutinin (HA) receptor binding domains of vaccine homologous Influenza A/Brisbane (H1N1 Subtype) strain calculated as GMT, defined as the antilog of the mean of the log-transformed HAI titers on Days 56, 70, and other follow-up time points. |
Not provided
Inclusion Criteria:
Healthy, medically stable adult males or females ≥ 50 to ≤ 70 years of age at screening.
Willing and able to give informed consent prior to study enrollment.
Able to attend study visits, comply with study requirements, and provide reliable and complete reports of AEs.
Participants must have been baseline seropositive to SARS-CoV-2 defined as either:
• Having completed a primary vaccination series against SARS-CoV-2 with an authorized COVID-19 vaccine with receipt of second/final dose of authorized vaccine ≥ 8 weeks prior to enrollment (first study vaccination).
OR
• Previously infected with SARS CoV-2 ≥ 8 weeks prior to enrollment (first study vaccination).
Note: Baseline SARS-CoV-2 serostatus determination at screening will be based on vaccination documentation (eg, vaccination card or vaccination registry) or participants' report of a previous SARS-CoV-2 infection.
Women of childbearing potential (defined as any female participant who is NOT surgically sterile [ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or postmenopausal [defined as amenorrhea at least 12 consecutive months]) must agree to be heterosexually inactive from at least 28 days prior to enrollment and through the end of the study OR agree to consistently use a medically acceptable method of contraception listed below from at least 28 days prior to enrollment and through the end of the study.
Participants must be healthy and medically stable, as determined by the investigator (based on a review of health status, vital signs [to include body temperature], medical history, and targeted physical examination [to include body weight]). Participants must have a body mass index (BMI) of 17 to 34 kg/m2, inclusive, at screening. Vital signs must be within medically acceptable ranges prior to the first vaccination.
Participants must agree to not participate in any other SARS-CoV-2 or influenza prevention or treatment studies for the duration of the study. Note: For participants who become hospitalized with COVID-19, participation in investigational treatment studies is permitted.
Exclusion Criteria:
Any ongoing, symptomatic acute, or chronic illness requiring medical or surgical care.
Participation in research involving an investigational product (drug/biologic/device) within 90 days before the planned date of the first injection.
Use of COVID-19 prophylactic or treatment monoclonal antibodies or antibody cocktails within 90 days prior to the planned date of the first injection.
History of a serious reaction to prior influenza vaccination or known allergy to constituents of influenza vaccines - including egg proteins - or polysorbate 80; or any known allergies to products contained in the investigational product.
Any history of anaphylaxis to any prior vaccine.
History of Guillain-Barré Syndrome within 6 weeks following a previous influenza vaccine.
Receipt of any vaccine in the 4 weeks preceding the study vaccination and any influenza vaccine within 2 months preceding the study vaccination. Note: Routine vaccinations will not be allowed until after study Day 70.
Any known or suspected autoimmune or immunosuppressive illness, congenital or acquired, based on medical history and/or physical examination.
Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccines. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose ≥ 10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.
Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study vaccine or during the study.
Active cancer (malignancy) therapy within 3 years prior to first study vaccination (with the exception of adequately treated non-melanomatous skin carcinoma or lentigo maligna and uterine cervical carcinoma in situ without evidence of disease, at the discretion of the investigator).
Participants who are breastfeeding, pregnant, or who plan to become pregnant prior to the EoS.
Known disturbance of coagulation.
Suspected or known history of alcohol abuse or drug addiction within 2 years prior to the first trial vaccine dose that, in the opinion of the investigator, might interfere with protocol compliance.
Acute disease at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature > 38.0°C, on the planned day of vaccine administration).
Any condition that in the opinion of the investigator would pose a health risk to the participant if enrolled or could interfere with evaluation of the vaccine or interpretation of study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).
Study team member or immediate family member of any study team member (inclusive of Sponsor, Contract Research Organization, and study site personnel involved in the conduct or planning of the study).
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Development | Novavax | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Paratus Clinical Research - Canberra | Bruce | Australian Capital Territory | 2617 | Australia | ||
| Paratus Clinical Research - Western Sydney |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Group A and Group C - ICC Vaccine Formulation | 2 doses of Formulation 1. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| FG001 |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | May 6, 2022 | Apr 26, 2023 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
2 doses of Formulation 6. 1 dose each on Days 0 and Day 56.
|
| Group H and Group N- ICC Vaccine Formulation | Experimental | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. |
|
| Group I- ICC Vaccine Formulation | Experimental | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. |
|
| Group J -ICC Vaccine Formulation | Experimental | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. |
|
| Group K - ICC Vaccine Formulation | Experimental | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. |
|
| Group L - ICC Vaccine Formulation | Experimental | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. |
|
| Group M -ICC Vaccine Formulation | Experimental | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. |
|
| Group O - qNIV with Matrix-M1 adjuvant | Experimental | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. |
|
| Group P- SARS-CoV-2 rS with Matrix-M1 adjuvant | Experimental | 2 doses of Formulation 14. 1 dose each on Days 0 and Day 56. |
|
| qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant | Biological | Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
| SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant | Biological | Intramuscular (deltoid) injections of 5 μg SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with 50 μg Matrix-M1 Adjuvant on Days 0 and Day 56. |
|
| Day 0 to Day 182 |
| Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Kansas (H3N2 Subtype) Strain Expressed as GMTs | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Kansas (H3N2 Subtype) strain calculated as GMT, defined as the antilog of the mean of the log-transformed HAI titers on Days 56, 70, and other follow-up time points. | Day 0 to Day 182 |
| Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Wisconsin (H1N1 Subtype) Strain Expressed as GMTs | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Wisconsin (H1N1 Subtype) strain calculated as GMT, defined as the antilog of the mean of the log-transformed HAI titers on Days 56, 70, and other follow-up time points. | Day 0 to Day 182 |
| Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Cambodia (H3N2 Subtype) Strain Expressed as GMTs | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Cambodia (H3N2 Subtype) strain calculated as GMT, defined as the antilog of the mean of the log-transformed HAI titers on Days 56, 70, and other follow-up time points. | Day 0 to Day 182 |
| Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Hong Kong (H3N2 Subtype) Strain Expressed as GMTs | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Hong Kong (H3N2 Subtype) strain calculated as GMT, defined as the antilog of the mean of the log-transformed HAI titers on Days 56, 70, and other follow-up time points. | Day 0 to Day 182 |
| Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Maryland (Victoria Subtype) Strain Expressed as GMTs | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza B/Maryland (Victoria Subtype) strain calculated as GMT, defined as the antilog of the mean of the log-transformed HAI titers on Days 56, 70, and other follow-up time points. | Day 0 to Day 182 |
| Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Phuket (Yamagata Subtype) Strain Expressed as GMTs | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza B/Phuket (Yamagata Subtype) strain calculated as GMT, defined as the antilog of the mean of the log-transformed HAI titers on Days 56, 70, and other follow-up time points. | Day 0 to Day 182 |
| Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Washington (Victoria Subtype) Strain Expressed as GMTs | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza B/Washington (Victoria Subtype) strain calculated as GMT, defined as the antilog of the mean of the log-transformed HAI titers on Days 56, 70, and other follow-up time points. | Day 0 to Day 182 |
| Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Brisbane (H1N1 Subtype) Expressed as Geometric Mean Fold Rise (GMFRPost/Pre) | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Brisbane (H1N1 Subtype) calculated as (GMFRPost/Pre), defined as the within-group ratio of post-vaccination to pre-vaccination (Day 0) HAI GMTs within the same vaccine group on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Kansas (H3N2 Subtype) Expressed as (GMFRPost/Pre) | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Kansas (H3N2 Subtype) calculated as (GMFRPost/Pre), defined as the within-group ratio of post-vaccination to pre-vaccination (Day 0) HAI GMTs within the same vaccine group on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Wisconsin (H1N1 Subtype) Expressed as (GMFRPost/Pre) | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Wisconsin (H1N1 Subtype) calculated as (GMFRPost/Pre), defined as the within-group ratio of post-vaccination to pre-vaccination (Day 0) HAI GMTs within the same vaccine group on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Cambodia (H3N2 Subtype) Expressed as (GMFRPost/Pre) | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Cambodia (H3N2 Subtype) calculated as (GMFRPost/Pre), defined as the within-group ratio of post-vaccination to pre-vaccination (Day 0) HAI GMTs within the same vaccine group on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Hong Kong (H3N2 Subtype) Expressed as (GMFRPost/Pre) | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Hong Kong (H3N2 Subtype) calculated as (GMFRPost/Pre), defined as the within-group ratio of post-vaccination to pre-vaccination (Day 0) HAI GMTs within the same vaccine group on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Maryland (Victoria Subtype) Expressed as (GMFRPost/Pre) | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza B/Maryland (Victoria Subtype) calculated as (GMFRPost/Pre), defined as the within-group ratio of post-vaccination to pre-vaccination (Day 0) HAI GMTs within the same vaccine group on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Phuket (Yamagata Subtype) Expressed as (GMFRPost/Pre) | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza B/Phuket (Yamagata Subtype) calculated as (GMFRPost/Pre), defined as the within-group ratio of post-vaccination to pre-vaccination (Day 0) HAI GMTs within the same vaccine group on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Washington (Victoria Subtype) Expressed as (GMFRPost/Pre) | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza B/Washington (Victoria Subtype) calculated as (GMFRPost/Pre), defined as the within-group ratio of post-vaccination to pre-vaccination (Day 0) HAI GMTs within the same vaccine group on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Brisbane (H1N1 Subtype) Strain Expressed as Seroconversion Rate (SCR) | Hemagglutination-Inhibition (HAI) Antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Brisbane (H1N1 Subtype) strain(s) calculated as SCR defined as the proportion of participants in a given treatment group with either a baseline reciprocal (Day 0) titer of < 10 and a post-vaccination reciprocal titer ≥ 40, or a baseline reciprocal (Day 0) titer of ≥ 10 and a post-vaccination titer ≥ 4-fold higher than the baseline titer as measured on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Kansas (H3N2 Subtype) Strain Expressed as SCR | Hemagglutination-Inhibition (HAI) Antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Kansas (H3N2 Subtype) strain(s) calculated as SCR defined as the proportion of participants in a given treatment group with either a baseline reciprocal (Day 0) titer of < 10 and a post-vaccination reciprocal titer ≥ 40, or a baseline reciprocal (Day 0) titer of ≥ 10 and a post-vaccination titer ≥ 4-fold higher than the baseline titer as measured on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Wisconsin (H1N1 Subtype) Strain Expressed as SCR | Hemagglutination-Inhibition (HAI) Antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Wisconsin (H1N1 Subtype) strain(s) calculated as SCR defined as the proportion of participants in a given treatment group with either a baseline reciprocal (Day 0) titer of < 10 and a post-vaccination reciprocal titer ≥ 40, or a baseline reciprocal (Day 0) titer of ≥ 10 and a post-vaccination titer ≥ 4-fold higher than the baseline titer as measured on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Cambodia (H3N2 Subtype) Strain Expressed as SCR | HAI antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Cambodia (H3N2 Subtype) strain(s) calculated as SCR defined as the proportion of participants in a given treatment group with either a baseline reciprocal (Day 0) titer of < 10 and a post-vaccination reciprocal titer ≥ 40, or a baseline reciprocal (Day 0) titer of ≥ 10 and a post-vaccination titer ≥ 4-fold higher than the baseline titer as measured on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Hong Kong (H3N2 Subtype) Strain Expressed as SCR | HAI antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Hong Kong (H3N2 Subtype)strain(s) calculated as SCR defined as the proportion of participants in a given treatment group with either a baseline reciprocal (Day 0) titer of < 10 and a post-vaccination reciprocal titer ≥ 40, or a baseline reciprocal (Day 0) titer of ≥ 10 and a post-vaccination titer ≥ 4-fold higher than the baseline titer as measured on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Maryland (Victoria Subtype) Strain Expressed as SCR | HAI antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza B/Maryland (Victoria Subtype) strain(s) calculated as SCR defined as the proportion of participants in a given treatment group with either a baseline reciprocal (Day 0) titer of < 10 and a post-vaccination reciprocal titer ≥ 40, or a baseline reciprocal (Day 0) titer of ≥ 10 and a post-vaccination titer ≥ 4-fold higher than the baseline titer as measured on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Phuket (Yamagata Subtype) Strain Expressed as SCR | HAI antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza B/Phuket (Yamagata Subtype) strain(s) calculated as SCR defined as the proportion of participants in a given treatment group with either a baseline reciprocal (Day 0) titer of < 10 and a post-vaccination reciprocal titer ≥ 40, or a baseline reciprocal (Day 0) titer of ≥ 10 and a post-vaccination titer ≥ 4-fold higher than the baseline titer as measured on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Washington (Victoria Subtype) Strain Expressed as SCR | HAI antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza B/Washington (Victoria Subtype) calculated as SCR defined as the proportion of participants in a given treatment group with either a baseline reciprocal (Day 0) titer of < 10 and a post-vaccination reciprocal titer ≥ 40, or a baseline reciprocal (Day 0) titer of ≥ 10 and a post-vaccination titer ≥ 4-fold higher than the baseline titer as measured on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Brisbane (H1N1 Subtype) Expressed as Geometric Mean Titer Ratio (GMTR) | GMT ratio (GMTR) between select treatment arms at Days 28,56, 70, and other follow-up time points post-vaccination (adjusted for intergroup variation in baseline [pre-vaccination] titers) | Day 28 to Day 182 |
| HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Kansas (H3N2 Subtype) Expressed as GMTR | GMT ratio (GMTR) between select treatment arms at Days 28,56, 70, and other follow-up time points post-vaccination (adjusted for intergroup variation in baseline [pre-vaccination] titers) | Day 28 to Day 182 |
| HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Wisconsin (H1N1 Subtype) Expressed as GMTR | GMT ratio (GMTR) between select treatment arms at Days 28,56, 70, and other follow-up time points post-vaccination (adjusted for intergroup variation in baseline [pre-vaccination] titers) | Day 28 to Day 182 |
| HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Cambodia (H3N2 Subtype) Expressed as GMTR | GMT ratio (GMTR) between select treatment arms at Days 28,56, 70, and other follow-up time points post-vaccination (adjusted for intergroup variation in baseline [pre-vaccination] titers) | Day 28 to Day 182 |
| HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Hong Kong (H3N2 Subtype) Expressed as GMTR | GMT ratio (GMTR) between select treatment arms at Days 28,56, 70, and other follow-up time points post-vaccination (adjusted for intergroup variation in baseline [pre-vaccination] titers) | Day 28 to Day 182 |
| HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Maryland (Victoria Subtype) Expressed as GMTR | GMT ratio (GMTR) between select treatment arms at Days 28,56, 70, and other follow-up time points post-vaccination (adjusted for intergroup variation in baseline [pre-vaccination] titers) | Day 28 to Day 182 |
| HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Phuket (Yamagata Subtype) Expressed as GMTR | GMT ratio (GMTR) between select treatment arms at Days 28,56, 70, and other follow-up time points post-vaccination (adjusted for intergroup variation in baseline [pre-vaccination] titers) | Day 28 to Day 182 |
| HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Washington (Victoria Subtype)Expressed as GMTR | GMT ratio (GMTR) between select treatment arms at Days 28,56, 70, and other follow-up time points post-vaccination (adjusted for intergroup variation in baseline [pre-vaccination] titers) | Day 28 to Day 182 |
| Percentage of Participants With a Reciprocal HAI Titer ≥ 40 Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Brisbane (H1N1 Subtype) Expressed as Seroprotection Rate (SPR). | Percentage of participants with a reciprocal HAI titer ≥ 40 specific for the HA receptor binding domains of vaccine homologous Influenza A/Brisbane (H1N1 Subtype) on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Percentage of Participants With a Reciprocal HAI Titer ≥ 40 Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Kansas (H3N2 Subtype) Expressed as SPR | Percentage of participants with a reciprocal HAI titer ≥ 40 specific for the HA receptor binding domains of vaccine homologous Influenza A/Kansas (H3N2 Subtype) on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Percentage of Participants With a Reciprocal HAI Titer ≥ 40 Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Wisconsin (H1N1 Subtype) Expressed as SPR | Percentage of participants with a reciprocal HAI titer ≥ 40 specific for the HA receptor binding domains of vaccine homologous Influenza A/Wisconsin (H1N1 Subtype) on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Percentage of Participants With a Reciprocal HAI Titer ≥ 40 Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Cambodia (H3N2 Subtype) Expressed as SPR | Percentage of participants with a reciprocal HAI titer ≥ 40 specific for the HA receptor binding domains of vaccine homologous Influenza A/Cambodia (H3N2 Subtype) on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Percentage of Participants With a Reciprocal HAI Titer ≥ 40 Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Hong Kong (H3N2 Subtype) Expressed as SPR | Percentage of participants with a reciprocal HAI titer ≥ 40 specific for the HA receptor binding domains of vaccine homologous Influenza A/Hong Kong (H3N2 Subtype)on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Percentage of Participants With a Reciprocal HAI Titer ≥ 40 Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Maryland (Victoria Subtype) Expressed as SPR | Percentage of participants with a reciprocal HAI titer ≥ 40 specific for the HA receptor binding domains of vaccine homologous Influenza B/Maryland (Victoria Subtype) on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Percentage of Participants With a Reciprocal HAI Titer ≥ 40 Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Phuket (Yamagata Subtype) Expressed as SPR | Percentage of participants with a reciprocal HAI titer ≥ 40 specific for the HA receptor binding domains of vaccine homologous Influenza B/Phuket (Yamagata Subtype) on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Percentage of Participants With a Reciprocal HAI Titer ≥ 40 Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Washington (Victoria Subtype) Expressed as SPR | Percentage of participants with a reciprocal HAI titer ≥ 40 specific for the HA receptor binding domains of vaccine homologous Influenza B/Washington (Victoria Subtype) on Days 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| MN50 GMTs to the SARS-CoV-2 Wuhan Strain Expressed as Geometric Mean Titers (GMT) | MN50 GMTs to the SARS-CoV-2 Wuhan Strain from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Day 0 to Day 182 |
| MN50 GMTs to the SARS-CoV-2 Omicron BA.1 Variant Expressed as GMT | MN50 GMTs to the SARS-CoV-2 Omicron BA.1 Variant from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Day 0 to Day 70 |
| MN50 GMTs to the SARS-CoV-2 Wuhan Strain Expressed as Geometric Mean Fold Rise (GMFR) | MN50 GMTs to the SARS-CoV-2 Wuhan Strain from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| MN50 GMTs to the SARS-CoV-2 Omicron BA.1 Variant Expressed as GMFR | MN50 GMTs to the SARS-CoV-2 Omicron BA.1 Variant from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Day 28 to Day 70 |
| MN50 GMTs to the SARS-CoV-2 Wuhan Strain Expressed as SCR | MN50 GMTs to the SARS-CoV-2 Wuhan Strain from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| MN50 GMTs to the SARS-CoV-2 Omicron BA.1 Variant Expressed as SCR | MN50 GMTs to the SARS-CoV-2 Omicron BA.1 Variant from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| MN50 GMTs to the SARS-CoV-2 Wuhan Strain Expressed as GMTR | MN50 GMTs to the SARS-CoV-2 Wuhan Strain from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| MN50 GMTs to the SARS-CoV-2 Omicron BA.1 Expressed as GMTR | MN50 GMTs to the SARS-CoV-2 Omicron BA.1 from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza A/Brisbane (H1N1 Subtype) Expressed as GMT | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza A/Brisbane (H1N1 Subtype) and/or antigenically-drifted influenza strains, as measured by an MN assay, expressed as GMT. | Day 0 to Day 182 |
| Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza A/Kansas (H3N2 Subtype) Expressed as GMT | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza A/Kansas (H3N2 Subtype) and/or antigenically-drifted influenza strains, as measured by an MN assay, expressed as GMT. | Day 0 to Day 182 |
| Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza A/Wisconsin (H1N1 Subtype) Expressed as GMT | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza A/Wisconsin (H1N1 Subtype) and/or antigenically-drifted influenza strains, as measured by an MN assay, expressed as GMT. | Day 0 to Day 182 |
| Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza A/Cambodia (H3N2 Subtype) Expressed as GMT | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza A/Cambodia (H3N2 Subtype) and/or antigenically-drifted influenza strains, as measured by an MN assay, expressed as GMT. | Day 0 to Day 182 |
| Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza A/Hong Kong (H3N2 Subtype) Expressed as GMT | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza A/Hong Kong (H3N2 Subtype) and/or antigenically-drifted influenza strains, as measured by an MN assay, expressed as GMT. | Day 0 to Day 182 |
| Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza B/Phuket (Yamagata Subtype) Expressed as GMT | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza B/Phuket (Yamagata Subtype) and/or antigenically-drifted influenza strains, as measured by an MN assay, expressed as GMT. | Day 0 to Day 182 |
| Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza B/Maryland (Victoria Subtype) Expressed as GMT | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza B/Maryland (Victoria Subtype) and/or antigenically-drifted influenza strains, as measured by an MN assay, expressed as GMT. | Day 0 to Day 182 |
| Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza B/Washington (Victoria Subtype)Expressed as GMT | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza B/Washington (Victoria Subtype) and/or antigenically-drifted influenza strains, as measured by an MN assay, expressed as GMT. | Day 0 to Day 182 |
| Microneutralization (MN50) Antibody Responses Influenza A/Brisbane (H1N1 Subtype) Expressed as GMFR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine Influenza A/Brisbane (H1N1 Subtype) antigenically-drifted influenza strains, as measured by a MN assay, expressed as GMFR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses Influenza A/Kansas (H3N2 Subtype) Expressed as GMFR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine Influenza A/Kansas (H3N2 Subtype) antigenically-drifted influenza strains, as measured by a MN assay, expressed as GMFR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses Influenza A/Wisconsin (H1N1 Subtype) Expressed as GMFR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine Influenza A/Wisconsin (H1N1 Subtype) antigenically-drifted influenza strains, as measured by a MN assay, expressed as GMFR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses Influenza A/Cambodia (H3N2 Subtype) Expressed as GMFR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine Influenza A/Cambodia (H3N2 Subtype) antigenically-drifted influenza strains, as measured by a MN assay, expressed as GMFR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses Influenza A/Hong Kong (H3N2 Subtype) Expressed as GMFR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine Influenza A/Hong Kong (H3N2 Subtype) antigenically-drifted influenza strains, as measured by a MN assay, expressed as GMFR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses Influenza B/Maryland (Victoria Subtype) Expressed as GMFR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine Influenza B/Maryland (Victoria Subtype) antigenically-drifted influenza strains, as measured by a MN assay, expressed as GMFR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses Influenza B/Phuket (Yamagata Subtype) Expressed as GMFR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine Influenza B/Phuket (Yamagata Subtype) antigenically-drifted influenza strains, as measured by a MN assay, expressed as GMFR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses Influenza B/Washington (Victoria Subtype) Expressed as GMFR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine Influenza B/Washington (Victoria Subtype) antigenically-drifted influenza strains, as measured by a MN assay, expressed as GMFR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses of Vaccine Homologous Influenza A/Brisbane (H1N1 Subtype) Strain Expressed as SCR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine of vaccine homologous Influenza A/Brisbane (H1N1 Subtype) strain expressed as SCR and/or antigenically-drifted influenza strains, as measured by a MN assay, expressed as SCR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses of Vaccine Homologous Influenza A/Kansas (H3N2 Subtype) Strain Expressed as SCR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine of vaccine homologous Influenza A/Kansas (H3N2 Subtype) strain expressed as SCR and/or antigenically-drifted influenza strains, as measured by a MN assay, expressed as SCR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses of Vaccine Homologous Influenza A/Wisconsin (H1N1 Subtype) Strain Expressed as SCR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine of vaccine homologous Influenza A/Wisconsin (H1N1 Subtype) strain expressed as SCR and/or antigenically-drifted influenza strains, as measured by a MN assay, expressed as SCR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses of Vaccine Homologous Influenza A/Cambodia (H3N2 Subtype) Strain Expressed as SCR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine of vaccine homologous Influenza A/Cambodia (H3N2 Subtype) strain expressed as SCR and/or antigenically-drifted influenza strains, as measured by a MN assay, expressed as SCR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses of Vaccine Homologous Influenza A/Hong Kong (H3N2 Subtype) Strain Expressed as SCR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine of vaccine homologous Influenza A/Hong Kong (H3N2 Subtype) strain expressed as SCR and/or antigenically-drifted influenza strains, as measured by a MN assay, expressed as SCR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses of Vaccine Homologous Influenza B/Maryland (Victoria Subtype) Strain Expressed as SCR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine of vaccine homologous Influenza B/Maryland (Victoria Subtype) strain expressed as SCR and/or antigenically-drifted influenza strains, as measured by a MN assay, expressed as SCR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses of Vaccine Homologous Influenza B/Phuket (Yamagata Subtype) Strain Expressed as SCR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine of vaccine homologous Influenza B/Phuket (Yamagata Subtype) strain expressed as SCR and/or antigenically-drifted influenza strains, as measured by a MN assay, expressed as SCR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses of Vaccine Homologous Influenza B/Washington (Victoria Subtype) Strain Expressed as SCR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine of vaccine homologous Influenza B/Washington (Victoria Subtype) strain expressed as SCR and/or antigenically-drifted influenza strains, as measured by a MN assay, expressed as SCR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza A/Brisbane (H1N1 Subtype) Expressed as GMTR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza A/Brisbane (H1N1 Subtype) and/or antigenically-drifted influenza strains, as measured by a MN assay , expressed as GMTR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza A/Kansas (H3N2 Subtype) Expressed as GMTR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza A/Kansas (H3N2 Subtype) and/or antigenically-drifted influenza strains, as measured by a MN assay , expressed as GMTR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza A/Wisconsin (H1N1 Subtype) Expressed as GMTR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza A/Wisconsin (H1N1 Subtype) and/or antigenically-drifted influenza strains, as measured by a MN assay , expressed as GMTR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza A/Cambodia (H3N2 Subtype) Expressed as GMTR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza A/Cambodia (H3N2 Subtype) and/or antigenically-drifted influenza strains, as measured by a MN assay , expressed as GMTR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza A/Hong Kong (H3N2 Subtype) Expressed as GMTR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza A/Hong Kong (H3N2 Subtype) and/or antigenically-drifted influenza strains, as measured by a MN assay , expressed as GMTR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza B/Maryland (Victoria Subtype)Expressed as GMTR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza B/Maryland (Victoria Subtype) and/or antigenically-drifted influenza strains, as measured by a MN assay , expressed as GMTR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza B/Phuket (Yamagata Subtype) Expressed as GMTR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza B/Phuket (Yamagata Subtype) and/or antigenically-drifted influenza strains, as measured by a MN assay , expressed as GMTR. | Day 28 to Day 182 |
| Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza B/Washington(VictoriaSubtype) Expressed as GMTR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza B/Washington(VictoriaSubtype) and/or antigenically-drifted influenza strains, as measured by a MN assay , expressed as GMTR. | Day 28 to Day 182 |
| Serum Immunoglobulin G (IgG) Antibody Concentrations as ELISA Units to the SARS-CoV-2 Wuhan Strain Spike Protein Expressed as Geometric Mean ELISA Unit (GMEU) | IgG geometric mean ELISA unit concentrations (EU/mL) to the SARS-CoV-2 Wuhan Strain spike protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Day 0 to Day 182 |
| Serum IgG Antibody Concentrations as ELISA Units to the SARS-CoV-2 Omicron BA.1 Variant Spike Protein Expressed as GMEU | IgG geometric mean ELISA unit concentrations (EU/mL) to the SARS-CoV-2 Omicron BA.1 spike protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Day 0 to Day 182 |
| Serum IgG Antibody Concentrations as ELISA Units to the SARS-CoV-2 Wuhan Strain Spike Protein Expressed as GMFR | IgG geometric mean ELISA unit concentrations (EU/mL) to the SARS-CoV-2 Wuhan Strain spike protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Serum IgG Antibody Concentrations as ELISA Units to the SARS-CoV-2 Omicron BA.1 Variant Spike Protein Expressed as GMFR | IgG geometric mean ELISA unit concentrations (EU/mL) to the SARS-CoV-2 Omicron BA.1 Variant spike protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Serum IgG Antibody Concentrations as ELISA Units to the SARS-CoV-2 Wuhan Strain Spike Protein Expressed as SCR | IgG geometric mean ELISA unit concentrations (EU/mL) to the SARS-CoV-2 Wuhan Strain spike protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Serum IgG Antibody Concentrations as ELISA Units to the SARS-CoV-2 Omicron BA.1 Variant Spike Protein Expressed as SCR | IgG geometric mean ELISA unit concentrations (EU/mL) to the SARS-CoV-2 Omicron BA.1 Variant spike protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Serum IgG Antibody Concentrations as ELISA Units to the SARS-CoV-2 Omicron BA.1 Variant Spike Protein Expressed as Geometric Mean ELISA Unit Ratio (GMEUR) | IgG geometric mean ELISA unit concentrations (EU/mL) to the SARS-CoV-2 Omicron BA.1 Variant spike protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Serum IgG Antibody Concentrations as ELISA Units to the SARS-CoV-2 (Wuhan) Spike Protein Expressed as GMEUR | IgG geometric mean ELISA unit concentrations (EU/mL) to the SARS-CoV-2 (Wuhan) spike protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Day 28 to Day 182 |
| Blacktown |
| New South Wales |
| 2148 |
| Australia |
| Northern Beaches Clinical Research | Brookvale | New South Wales | 2100 | Australia |
| Paratus Clinical Research - Central Coast | Kanwal | New South Wales | 2259 | Australia |
| Hunter Diabetes Centre | Merewether | New South Wales | 2291 | Australia |
| University of the Sunshine Coast,Southbank | Brisbane | Queensland | 4101 | Australia |
| University of the Sunshine Coast, Health Hub Morayfield | Morayfield | Queensland | 4506 | Australia |
| University of the Sunshine Coast | Sippy Downs | Queensland | 4556 | Australia |
| Austrials Pty Ltd - Taringa | Taringa | Queensland | 4068 | Australia |
| Emeritus Research | Camberwell | Victoria | 3214 | Australia |
| Group B -ICC Vaccine Formulation |
2 doses of Formulation 2. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| FG002 | Group D - ICC Vaccine Formulation | 2 doses of Formulation 3. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| FG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| FG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| FG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| FG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| FG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| FG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| FG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| FG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| FG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| FG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
| FG013 | Group P- SARS-CoV-2 rS With Matrix-M1 Adjuvant | 2 doses of Formulation 14. 1 dose each on Days 0 and Day 56. SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 5 μg SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with 50 μg Matrix-M1 Adjuvant on Days 0 and Day 56. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Safety Analysis Set Population
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Group A and Group C - ICC Vaccine Formulation | 2 doses of Formulation 1. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| BG001 | Group B -ICC Vaccine Formulation | 2 doses of Formulation 2. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| BG002 | Group D - ICC Vaccine Formulation | 2 doses of Formulation 3. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| BG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| BG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| BG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| BG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| BG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| BG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| BG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| BG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| BG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| BG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
| BG013 | Group P- SARS-CoV-2 rS With Matrix-M1 Adjuvant | 2 doses of Formulation 14. 1 dose each on Days 0 and Day 56. SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 5 μg SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with 50 μg Matrix-M1 Adjuvant on Days 0 and Day 56. |
| BG014 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Regimen of Previous COVID Vaccine | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Solicited Local and Systemic Adverse Events (AE's) | Numbers of participants with solicited local and systemic AEs over the 7 days post-injection after first and second doses. | Safety Analysis Set Population | Posted | Number | participants | Day 0 to Day 63 |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants Reporting All AE's | Number of participants reporting all AEs, (solicited and unsolicited), over 70 days after the first dose. | Posted | Count of Participants | Participants | No | Day 0 to Day 70 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With MAAEs, AESIs (Including PIMMCs), SAEs | Number of participants with Medical Attended Adverse Events (MAAE's), Adverse events (AESI's), Including potential immune-mediated medical conditions (PIMMCs), Serious Adverse Events SAEs. | Safety Analysis Set | Posted | Count of Participants | Participants | Day 0 to Day 180 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the Hemagglutinin (HA) Receptor Binding Domains of Vaccine Homologous Influenza A/Brisbane (H1N1 Subtype) Strain Expressed as Geometric Mean Titers (GMTs) | Hemagglutination-inhibition (HAI) antibody titers specific for the hemagglutinin (HA) receptor binding domains of vaccine homologous Influenza A/Brisbane (H1N1 Subtype) strain calculated as GMT, defined as the antilog of the mean of the log-transformed HAI titers on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | Geometric Mean Titers | Day 0 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Kansas (H3N2 Subtype) Strain Expressed as GMTs | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Kansas (H3N2 Subtype) strain calculated as GMT, defined as the antilog of the mean of the log-transformed HAI titers on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | Geometric Mean Titers | Day 0 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Wisconsin (H1N1 Subtype) Strain Expressed as GMTs | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Wisconsin (H1N1 Subtype) strain calculated as GMT, defined as the antilog of the mean of the log-transformed HAI titers on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | Geometric Mean Titers | Day 0 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Cambodia (H3N2 Subtype) Strain Expressed as GMTs | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Cambodia (H3N2 Subtype) strain calculated as GMT, defined as the antilog of the mean of the log-transformed HAI titers on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | Geometric Mean Titers | Day 0 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Hong Kong (H3N2 Subtype) Strain Expressed as GMTs | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Hong Kong (H3N2 Subtype) strain calculated as GMT, defined as the antilog of the mean of the log-transformed HAI titers on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | Geometric Mean Titers | Day 0 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Maryland (Victoria Subtype) Strain Expressed as GMTs | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza B/Maryland (Victoria Subtype) strain calculated as GMT, defined as the antilog of the mean of the log-transformed HAI titers on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | Geometric Mean Titers | Day 0 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Phuket (Yamagata Subtype) Strain Expressed as GMTs | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza B/Phuket (Yamagata Subtype) strain calculated as GMT, defined as the antilog of the mean of the log-transformed HAI titers on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | Geometric Mean Titers | Day 0 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Washington (Victoria Subtype) Strain Expressed as GMTs | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza B/Washington (Victoria Subtype) strain calculated as GMT, defined as the antilog of the mean of the log-transformed HAI titers on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | Geometric Mean Titers | Day 0 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Brisbane (H1N1 Subtype) Expressed as Geometric Mean Fold Rise (GMFRPost/Pre) | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Brisbane (H1N1 Subtype) calculated as (GMFRPost/Pre), defined as the within-group ratio of post-vaccination to pre-vaccination (Day 0) HAI GMTs within the same vaccine group on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean fold rise | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Kansas (H3N2 Subtype) Expressed as (GMFRPost/Pre) | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Kansas (H3N2 Subtype) calculated as (GMFRPost/Pre), defined as the within-group ratio of post-vaccination to pre-vaccination (Day 0) HAI GMTs within the same vaccine group on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean fold rise | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Wisconsin (H1N1 Subtype) Expressed as (GMFRPost/Pre) | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Wisconsin (H1N1 Subtype) calculated as (GMFRPost/Pre), defined as the within-group ratio of post-vaccination to pre-vaccination (Day 0) HAI GMTs within the same vaccine group on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean fold rise | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Cambodia (H3N2 Subtype) Expressed as (GMFRPost/Pre) | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Cambodia (H3N2 Subtype) calculated as (GMFRPost/Pre), defined as the within-group ratio of post-vaccination to pre-vaccination (Day 0) HAI GMTs within the same vaccine group on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean fold rise | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Hong Kong (H3N2 Subtype) Expressed as (GMFRPost/Pre) | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Hong Kong (H3N2 Subtype) calculated as (GMFRPost/Pre), defined as the within-group ratio of post-vaccination to pre-vaccination (Day 0) HAI GMTs within the same vaccine group on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean fold rise | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Maryland (Victoria Subtype) Expressed as (GMFRPost/Pre) | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza B/Maryland (Victoria Subtype) calculated as (GMFRPost/Pre), defined as the within-group ratio of post-vaccination to pre-vaccination (Day 0) HAI GMTs within the same vaccine group on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean fold rise | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Phuket (Yamagata Subtype) Expressed as (GMFRPost/Pre) | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza B/Phuket (Yamagata Subtype) calculated as (GMFRPost/Pre), defined as the within-group ratio of post-vaccination to pre-vaccination (Day 0) HAI GMTs within the same vaccine group on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean fold rise | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Washington (Victoria Subtype) Expressed as (GMFRPost/Pre) | Hemagglutination-inhibition (HAI) antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza B/Washington (Victoria Subtype) calculated as (GMFRPost/Pre), defined as the within-group ratio of post-vaccination to pre-vaccination (Day 0) HAI GMTs within the same vaccine group on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean fold rise | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Brisbane (H1N1 Subtype) Strain Expressed as Seroconversion Rate (SCR) | Hemagglutination-Inhibition (HAI) Antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Brisbane (H1N1 Subtype) strain(s) calculated as SCR defined as the proportion of participants in a given treatment group with either a baseline reciprocal (Day 0) titer of < 10 and a post-vaccination reciprocal titer ≥ 40, or a baseline reciprocal (Day 0) titer of ≥ 10 and a post-vaccination titer ≥ 4-fold higher than the baseline titer as measured on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Kansas (H3N2 Subtype) Strain Expressed as SCR | Hemagglutination-Inhibition (HAI) Antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Kansas (H3N2 Subtype) strain(s) calculated as SCR defined as the proportion of participants in a given treatment group with either a baseline reciprocal (Day 0) titer of < 10 and a post-vaccination reciprocal titer ≥ 40, or a baseline reciprocal (Day 0) titer of ≥ 10 and a post-vaccination titer ≥ 4-fold higher than the baseline titer as measured on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Hemagglutination-Inhibition (HAI) Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Wisconsin (H1N1 Subtype) Strain Expressed as SCR | Hemagglutination-Inhibition (HAI) Antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Wisconsin (H1N1 Subtype) strain(s) calculated as SCR defined as the proportion of participants in a given treatment group with either a baseline reciprocal (Day 0) titer of < 10 and a post-vaccination reciprocal titer ≥ 40, or a baseline reciprocal (Day 0) titer of ≥ 10 and a post-vaccination titer ≥ 4-fold higher than the baseline titer as measured on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Cambodia (H3N2 Subtype) Strain Expressed as SCR | HAI antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Cambodia (H3N2 Subtype) strain(s) calculated as SCR defined as the proportion of participants in a given treatment group with either a baseline reciprocal (Day 0) titer of < 10 and a post-vaccination reciprocal titer ≥ 40, or a baseline reciprocal (Day 0) titer of ≥ 10 and a post-vaccination titer ≥ 4-fold higher than the baseline titer as measured on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Hong Kong (H3N2 Subtype) Strain Expressed as SCR | HAI antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza A/Hong Kong (H3N2 Subtype)strain(s) calculated as SCR defined as the proportion of participants in a given treatment group with either a baseline reciprocal (Day 0) titer of < 10 and a post-vaccination reciprocal titer ≥ 40, or a baseline reciprocal (Day 0) titer of ≥ 10 and a post-vaccination titer ≥ 4-fold higher than the baseline titer as measured on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Maryland (Victoria Subtype) Strain Expressed as SCR | HAI antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza B/Maryland (Victoria Subtype) strain(s) calculated as SCR defined as the proportion of participants in a given treatment group with either a baseline reciprocal (Day 0) titer of < 10 and a post-vaccination reciprocal titer ≥ 40, or a baseline reciprocal (Day 0) titer of ≥ 10 and a post-vaccination titer ≥ 4-fold higher than the baseline titer as measured on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Phuket (Yamagata Subtype) Strain Expressed as SCR | HAI antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza B/Phuket (Yamagata Subtype) strain(s) calculated as SCR defined as the proportion of participants in a given treatment group with either a baseline reciprocal (Day 0) titer of < 10 and a post-vaccination reciprocal titer ≥ 40, or a baseline reciprocal (Day 0) titer of ≥ 10 and a post-vaccination titer ≥ 4-fold higher than the baseline titer as measured on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Washington (Victoria Subtype) Strain Expressed as SCR | HAI antibody titers specific for the HA receptor binding domains of vaccine homologous Influenza B/Washington (Victoria Subtype) calculated as SCR defined as the proportion of participants in a given treatment group with either a baseline reciprocal (Day 0) titer of < 10 and a post-vaccination reciprocal titer ≥ 40, or a baseline reciprocal (Day 0) titer of ≥ 10 and a post-vaccination titer ≥ 4-fold higher than the baseline titer as measured on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Brisbane (H1N1 Subtype) Expressed as Geometric Mean Titer Ratio (GMTR) | GMT ratio (GMTR) between select treatment arms at Days 28,56, 70, and other follow-up time points post-vaccination (adjusted for intergroup variation in baseline [pre-vaccination] titers) | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | Geometric mean titer ratio | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Kansas (H3N2 Subtype) Expressed as GMTR | GMT ratio (GMTR) between select treatment arms at Days 28,56, 70, and other follow-up time points post-vaccination (adjusted for intergroup variation in baseline [pre-vaccination] titers) | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | Geometric mean titer ratio | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Wisconsin (H1N1 Subtype) Expressed as GMTR | GMT ratio (GMTR) between select treatment arms at Days 28,56, 70, and other follow-up time points post-vaccination (adjusted for intergroup variation in baseline [pre-vaccination] titers) | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | Geometric mean titer ratio | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Cambodia (H3N2 Subtype) Expressed as GMTR | GMT ratio (GMTR) between select treatment arms at Days 28,56, 70, and other follow-up time points post-vaccination (adjusted for intergroup variation in baseline [pre-vaccination] titers) | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | Geometric mean titer ratio | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Hong Kong (H3N2 Subtype) Expressed as GMTR | GMT ratio (GMTR) between select treatment arms at Days 28,56, 70, and other follow-up time points post-vaccination (adjusted for intergroup variation in baseline [pre-vaccination] titers) | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | Geometric mean titer ratio | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Maryland (Victoria Subtype) Expressed as GMTR | GMT ratio (GMTR) between select treatment arms at Days 28,56, 70, and other follow-up time points post-vaccination (adjusted for intergroup variation in baseline [pre-vaccination] titers) | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | Geometric mean titer ratio | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Phuket (Yamagata Subtype) Expressed as GMTR | GMT ratio (GMTR) between select treatment arms at Days 28,56, 70, and other follow-up time points post-vaccination (adjusted for intergroup variation in baseline [pre-vaccination] titers) | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | Geometric mean titer ratio | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | HAI Antibody Titers Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Washington (Victoria Subtype)Expressed as GMTR | GMT ratio (GMTR) between select treatment arms at Days 28,56, 70, and other follow-up time points post-vaccination (adjusted for intergroup variation in baseline [pre-vaccination] titers) | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | Geometric mean titer ratio | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With a Reciprocal HAI Titer ≥ 40 Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Brisbane (H1N1 Subtype) Expressed as Seroprotection Rate (SPR). | Percentage of participants with a reciprocal HAI titer ≥ 40 specific for the HA receptor binding domains of vaccine homologous Influenza A/Brisbane (H1N1 Subtype) on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | percentage of participants(SPR) | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With a Reciprocal HAI Titer ≥ 40 Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Kansas (H3N2 Subtype) Expressed as SPR | Percentage of participants with a reciprocal HAI titer ≥ 40 specific for the HA receptor binding domains of vaccine homologous Influenza A/Kansas (H3N2 Subtype) on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | percentage of participants(SPR) | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With a Reciprocal HAI Titer ≥ 40 Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Wisconsin (H1N1 Subtype) Expressed as SPR | Percentage of participants with a reciprocal HAI titer ≥ 40 specific for the HA receptor binding domains of vaccine homologous Influenza A/Wisconsin (H1N1 Subtype) on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With a Reciprocal HAI Titer ≥ 40 Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Cambodia (H3N2 Subtype) Expressed as SPR | Percentage of participants with a reciprocal HAI titer ≥ 40 specific for the HA receptor binding domains of vaccine homologous Influenza A/Cambodia (H3N2 Subtype) on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With a Reciprocal HAI Titer ≥ 40 Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza A/Hong Kong (H3N2 Subtype) Expressed as SPR | Percentage of participants with a reciprocal HAI titer ≥ 40 specific for the HA receptor binding domains of vaccine homologous Influenza A/Hong Kong (H3N2 Subtype)on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | percentage of participants(SPR) | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With a Reciprocal HAI Titer ≥ 40 Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Maryland (Victoria Subtype) Expressed as SPR | Percentage of participants with a reciprocal HAI titer ≥ 40 specific for the HA receptor binding domains of vaccine homologous Influenza B/Maryland (Victoria Subtype) on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With a Reciprocal HAI Titer ≥ 40 Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Phuket (Yamagata Subtype) Expressed as SPR | Percentage of participants with a reciprocal HAI titer ≥ 40 specific for the HA receptor binding domains of vaccine homologous Influenza B/Phuket (Yamagata Subtype) on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | percentage of participants(SPR) | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With a Reciprocal HAI Titer ≥ 40 Specific for the HA Receptor Binding Domains of Vaccine Homologous Influenza B/Washington (Victoria Subtype) Expressed as SPR | Percentage of participants with a reciprocal HAI titer ≥ 40 specific for the HA receptor binding domains of vaccine homologous Influenza B/Washington (Victoria Subtype) on Days 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | percentage of participants(SPR) | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | MN50 GMTs to the SARS-CoV-2 Wuhan Strain Expressed as Geometric Mean Titers (GMT) | MN50 GMTs to the SARS-CoV-2 Wuhan Strain from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean titer | Day 0 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | MN50 GMTs to the SARS-CoV-2 Omicron BA.1 Variant Expressed as GMT | MN50 GMTs to the SARS-CoV-2 Omicron BA.1 Variant from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean titer | Day 0 to Day 70 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | MN50 GMTs to the SARS-CoV-2 Wuhan Strain Expressed as Geometric Mean Fold Rise (GMFR) | MN50 GMTs to the SARS-CoV-2 Wuhan Strain from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean fold rise | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | MN50 GMTs to the SARS-CoV-2 Omicron BA.1 Variant Expressed as GMFR | MN50 GMTs to the SARS-CoV-2 Omicron BA.1 Variant from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean fold rise | Day 28 to Day 70 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | MN50 GMTs to the SARS-CoV-2 Wuhan Strain Expressed as SCR | MN50 GMTs to the SARS-CoV-2 Wuhan Strain from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | Percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | MN50 GMTs to the SARS-CoV-2 Omicron BA.1 Variant Expressed as SCR | MN50 GMTs to the SARS-CoV-2 Omicron BA.1 Variant from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | Percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | MN50 GMTs to the SARS-CoV-2 Wuhan Strain Expressed as GMTR | MN50 GMTs to the SARS-CoV-2 Wuhan Strain from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | Geometric mean titer ratio | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | MN50 GMTs to the SARS-CoV-2 Omicron BA.1 Expressed as GMTR | MN50 GMTs to the SARS-CoV-2 Omicron BA.1 from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | Geometric mean titer ratio | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza A/Brisbane (H1N1 Subtype) Expressed as GMT | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza A/Brisbane (H1N1 Subtype) and/or antigenically-drifted influenza strains, as measured by an MN assay, expressed as GMT. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean titer | Day 0 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza A/Kansas (H3N2 Subtype) Expressed as GMT | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza A/Kansas (H3N2 Subtype) and/or antigenically-drifted influenza strains, as measured by an MN assay, expressed as GMT. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean titer | Day 0 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza A/Wisconsin (H1N1 Subtype) Expressed as GMT | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza A/Wisconsin (H1N1 Subtype) and/or antigenically-drifted influenza strains, as measured by an MN assay, expressed as GMT. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean titer | Day 0 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza A/Cambodia (H3N2 Subtype) Expressed as GMT | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza A/Cambodia (H3N2 Subtype) and/or antigenically-drifted influenza strains, as measured by an MN assay, expressed as GMT. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean titer | Day 0 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza A/Hong Kong (H3N2 Subtype) Expressed as GMT | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza A/Hong Kong (H3N2 Subtype) and/or antigenically-drifted influenza strains, as measured by an MN assay, expressed as GMT. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean titer | Day 0 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza B/Phuket (Yamagata Subtype) Expressed as GMT | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza B/Phuket (Yamagata Subtype) and/or antigenically-drifted influenza strains, as measured by an MN assay, expressed as GMT. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean titer | Day 0 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza B/Maryland (Victoria Subtype) Expressed as GMT | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza B/Maryland (Victoria Subtype) and/or antigenically-drifted influenza strains, as measured by an MN assay, expressed as GMT. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean titer | Day 0 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza B/Washington (Victoria Subtype)Expressed as GMT | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza B/Washington (Victoria Subtype) and/or antigenically-drifted influenza strains, as measured by an MN assay, expressed as GMT. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean titer | Day 0 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Influenza A/Brisbane (H1N1 Subtype) Expressed as GMFR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine Influenza A/Brisbane (H1N1 Subtype) antigenically-drifted influenza strains, as measured by a MN assay, expressed as GMFR. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean fold rise | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Influenza A/Kansas (H3N2 Subtype) Expressed as GMFR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine Influenza A/Kansas (H3N2 Subtype) antigenically-drifted influenza strains, as measured by a MN assay, expressed as GMFR. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean fold rise | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Influenza A/Wisconsin (H1N1 Subtype) Expressed as GMFR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine Influenza A/Wisconsin (H1N1 Subtype) antigenically-drifted influenza strains, as measured by a MN assay, expressed as GMFR. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean fold rise | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Influenza A/Cambodia (H3N2 Subtype) Expressed as GMFR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine Influenza A/Cambodia (H3N2 Subtype) antigenically-drifted influenza strains, as measured by a MN assay, expressed as GMFR. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean fold rise | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Influenza A/Hong Kong (H3N2 Subtype) Expressed as GMFR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine Influenza A/Hong Kong (H3N2 Subtype) antigenically-drifted influenza strains, as measured by a MN assay, expressed as GMFR. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean fold rise | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Influenza B/Maryland (Victoria Subtype) Expressed as GMFR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine Influenza B/Maryland (Victoria Subtype) antigenically-drifted influenza strains, as measured by a MN assay, expressed as GMFR. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean fold rise | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Influenza B/Phuket (Yamagata Subtype) Expressed as GMFR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine Influenza B/Phuket (Yamagata Subtype) antigenically-drifted influenza strains, as measured by a MN assay, expressed as GMFR. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean fold rise | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Influenza B/Washington (Victoria Subtype) Expressed as GMFR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine Influenza B/Washington (Victoria Subtype) antigenically-drifted influenza strains, as measured by a MN assay, expressed as GMFR. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean fold rise | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses of Vaccine Homologous Influenza A/Brisbane (H1N1 Subtype) Strain Expressed as SCR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine of vaccine homologous Influenza A/Brisbane (H1N1 Subtype) strain expressed as SCR and/or antigenically-drifted influenza strains, as measured by a MN assay, expressed as SCR. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | Percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses of Vaccine Homologous Influenza A/Kansas (H3N2 Subtype) Strain Expressed as SCR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine of vaccine homologous Influenza A/Kansas (H3N2 Subtype) strain expressed as SCR and/or antigenically-drifted influenza strains, as measured by a MN assay, expressed as SCR. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | Percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses of Vaccine Homologous Influenza A/Wisconsin (H1N1 Subtype) Strain Expressed as SCR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine of vaccine homologous Influenza A/Wisconsin (H1N1 Subtype) strain expressed as SCR and/or antigenically-drifted influenza strains, as measured by a MN assay, expressed as SCR. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | Percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses of Vaccine Homologous Influenza A/Cambodia (H3N2 Subtype) Strain Expressed as SCR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine of vaccine homologous Influenza A/Cambodia (H3N2 Subtype) strain expressed as SCR and/or antigenically-drifted influenza strains, as measured by a MN assay, expressed as SCR. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | Percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses of Vaccine Homologous Influenza A/Hong Kong (H3N2 Subtype) Strain Expressed as SCR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine of vaccine homologous Influenza A/Hong Kong (H3N2 Subtype) strain expressed as SCR and/or antigenically-drifted influenza strains, as measured by a MN assay, expressed as SCR. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | Percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses of Vaccine Homologous Influenza B/Maryland (Victoria Subtype) Strain Expressed as SCR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine of vaccine homologous Influenza B/Maryland (Victoria Subtype) strain expressed as SCR and/or antigenically-drifted influenza strains, as measured by a MN assay, expressed as SCR. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | Percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses of Vaccine Homologous Influenza B/Phuket (Yamagata Subtype) Strain Expressed as SCR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine of vaccine homologous Influenza B/Phuket (Yamagata Subtype) strain expressed as SCR and/or antigenically-drifted influenza strains, as measured by a MN assay, expressed as SCR. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | Percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses of Vaccine Homologous Influenza B/Washington (Victoria Subtype) Strain Expressed as SCR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine of vaccine homologous Influenza B/Washington (Victoria Subtype) strain expressed as SCR and/or antigenically-drifted influenza strains, as measured by a MN assay, expressed as SCR. | Per-Protocol Analysis Set Population | Posted | Number | 95% Confidence Interval | Percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza A/Brisbane (H1N1 Subtype) Expressed as GMTR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza A/Brisbane (H1N1 Subtype) and/or antigenically-drifted influenza strains, as measured by a MN assay , expressed as GMTR. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | Geometric mean titer ratio | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza A/Kansas (H3N2 Subtype) Expressed as GMTR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza A/Kansas (H3N2 Subtype) and/or antigenically-drifted influenza strains, as measured by a MN assay , expressed as GMTR. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | Geometric mean titer ratio | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza A/Wisconsin (H1N1 Subtype) Expressed as GMTR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza A/Wisconsin (H1N1 Subtype) and/or antigenically-drifted influenza strains, as measured by a MN assay , expressed as GMTR. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | Geometric mean titer ratio | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza A/Cambodia (H3N2 Subtype) Expressed as GMTR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza A/Cambodia (H3N2 Subtype) and/or antigenically-drifted influenza strains, as measured by a MN assay , expressed as GMTR. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | Geometric mean titer ratio | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza A/Hong Kong (H3N2 Subtype) Expressed as GMTR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza A/Hong Kong (H3N2 Subtype) and/or antigenically-drifted influenza strains, as measured by a MN assay , expressed as GMTR. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | Geometric mean titer ratio | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza B/Maryland (Victoria Subtype)Expressed as GMTR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza B/Maryland (Victoria Subtype) and/or antigenically-drifted influenza strains, as measured by a MN assay , expressed as GMTR. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | Geometric mean titer ratio | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza B/Phuket (Yamagata Subtype) Expressed as GMTR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza B/Phuket (Yamagata Subtype) and/or antigenically-drifted influenza strains, as measured by a MN assay , expressed as GMTR. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | Geometric mean titer ratio | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Microneutralization (MN50) Antibody Responses Specific to Vaccine Homologous Wild-type Influenza B/Washington(VictoriaSubtype) Expressed as GMTR | Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type Influenza B/Washington(VictoriaSubtype) and/or antigenically-drifted influenza strains, as measured by a MN assay , expressed as GMTR. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | Geometric mean titer ratio | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Serum Immunoglobulin G (IgG) Antibody Concentrations as ELISA Units to the SARS-CoV-2 Wuhan Strain Spike Protein Expressed as Geometric Mean ELISA Unit (GMEU) | IgG geometric mean ELISA unit concentrations (EU/mL) to the SARS-CoV-2 Wuhan Strain spike protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | EU/mL | Day 0 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Serum IgG Antibody Concentrations as ELISA Units to the SARS-CoV-2 Omicron BA.1 Variant Spike Protein Expressed as GMEU | IgG geometric mean ELISA unit concentrations (EU/mL) to the SARS-CoV-2 Omicron BA.1 spike protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | EU/mL | Day 0 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Serum IgG Antibody Concentrations as ELISA Units to the SARS-CoV-2 Wuhan Strain Spike Protein Expressed as GMFR | IgG geometric mean ELISA unit concentrations (EU/mL) to the SARS-CoV-2 Wuhan Strain spike protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean fold rise | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Serum IgG Antibody Concentrations as ELISA Units to the SARS-CoV-2 Omicron BA.1 Variant Spike Protein Expressed as GMFR | IgG geometric mean ELISA unit concentrations (EU/mL) to the SARS-CoV-2 Omicron BA.1 Variant spike protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Per Protocol Analysis Set population | Posted | Geometric Mean | 95% Confidence Interval | geometric mean fold rise | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Serum IgG Antibody Concentrations as ELISA Units to the SARS-CoV-2 Wuhan Strain Spike Protein Expressed as SCR | IgG geometric mean ELISA unit concentrations (EU/mL) to the SARS-CoV-2 Wuhan Strain spike protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Per Protocol Analysis Set | Posted | Number | 95% Confidence Interval | Percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Serum IgG Antibody Concentrations as ELISA Units to the SARS-CoV-2 Omicron BA.1 Variant Spike Protein Expressed as SCR | IgG geometric mean ELISA unit concentrations (EU/mL) to the SARS-CoV-2 Omicron BA.1 Variant spike protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Per Protocol Analysis Set | Posted | Number | 95% Confidence Interval | Percentage of participants | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Serum IgG Antibody Concentrations as ELISA Units to the SARS-CoV-2 Omicron BA.1 Variant Spike Protein Expressed as Geometric Mean ELISA Unit Ratio (GMEUR) | IgG geometric mean ELISA unit concentrations (EU/mL) to the SARS-CoV-2 Omicron BA.1 Variant spike protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | ratio | Day 28 to Day 182 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Serum IgG Antibody Concentrations as ELISA Units to the SARS-CoV-2 (Wuhan) Spike Protein Expressed as GMEUR | IgG geometric mean ELISA unit concentrations (EU/mL) to the SARS-CoV-2 (Wuhan) spike protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points. | Per-Protocol Analysis Set Population | Posted | Geometric Mean | 95% Confidence Interval | ratio | Day 28 to Day 182 |
|
6 Month
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Group A and Group C - ICC Vaccine Formulation | 2 doses of Formulation 1. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. | 0 | 80 | 2 | 80 | 8 | 80 |
| EG001 | Group B -ICC Vaccine Formulation | 2 doses of Formulation 2. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. | 0 | 40 | 1 | 40 | 6 | 40 |
| EG002 | Group D - ICC Vaccine Formulation | 2 doses of Formulation 3. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. | 0 | 39 | 2 | 39 | 12 | 39 |
| EG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. | 0 | 37 | 0 | 37 | 13 | 37 |
| EG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. | 0 | 41 | 2 | 41 | 7 | 41 |
| EG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. | 0 | 41 | 1 | 41 | 8 | 41 |
| EG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. | 0 | 81 | 3 | 81 | 19 | 81 |
| EG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. | 0 | 39 | 2 | 39 | 5 | 39 |
| EG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. | 0 | 39 | 0 | 39 | 7 | 39 |
| EG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. | 0 | 40 | 0 | 40 | 2 | 40 |
| EG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. | 0 | 40 | 5 | 40 | 4 | 40 |
| EG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. | 0 | 41 | 0 | 41 | 8 | 41 |
| EG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. | 0 | 39 | 1 | 39 | 6 | 39 |
| EG013 | Group P- SARS-CoV-2 rS With Matrix-M1 Adjuvant | 2 doses of Formulation 14. 1 dose each on Days 0 and Day 56. SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 5 μg SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with 50 μg Matrix-M1 Adjuvant on Days 0 and Day 56. | 0 | 40 | 1 | 40 | 4 | 40 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Acute myocardial infarction | Cardiac disorders | MedDRA (12.0) | Systematic Assessment |
| |
| Coronary artery disease | Cardiac disorders | MedDRA (12.0) | Systematic Assessment |
| |
| Supraventricular tachycardia | Cardiac disorders | MedDRA (12.0) | Systematic Assessment |
| |
| Ventricular fibrillation | Cardiac disorders | MedDRA (12.0) | Systematic Assessment |
| |
| Infected bite | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
| |
| Sialoadenitis | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
| |
| Fall | Injury, poisoning and procedural complications | MedDRA (12.0) | Systematic Assessment |
| |
| Head injury | Injury, poisoning and procedural complications | MedDRA (12.0) | Systematic Assessment |
| |
| Joint dislocation | Injury, poisoning and procedural complications | MedDRA (12.0) | Systematic Assessment |
| |
| Pelvic fracture | Injury, poisoning and procedural complications | MedDRA (12.0) | Systematic Assessment |
| |
| Scapula fracture | Injury, poisoning and procedural complications | MedDRA (12.0) | Systematic Assessment |
| |
| Arthritis | Musculoskeletal and connective tissue disorders | MedDRA (12.0) | Systematic Assessment |
| |
| Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | MedDRA (12.0) | Systematic Assessment |
| |
| Joint instability | Musculoskeletal and connective tissue disorders | MedDRA (12.0) | Systematic Assessment |
| |
| Transitional cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (12.0) | Systematic Assessment |
| |
| Ischaemic stroke | Nervous system disorders | MedDRA (12.0) | Systematic Assessment |
| |
| Hydronephrosis | Renal and urinary disorders | MedDRA (12.0) | Systematic Assessment |
| |
| Epistaxis | Respiratory, thoracic and mediastinal disorders | MedDRA (12.0) | Systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA (12.0) | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Ear pain | Ear and labyrinth disorders | MedDRA (12.0) | Systematic Assessment |
| |
| Injection site erythema | General disorders | MedDRA (12.0) | Systematic Assessment |
| |
| Diverticulitis | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
| |
| Gastroenteritis | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
| |
| Rhinitis | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA (12.0) | Systematic Assessment |
| |
| Skin abrasion | Injury, poisoning and procedural complications | MedDRA (12.0) | Systematic Assessment |
| |
| Skin laceration | Injury, poisoning and procedural complications | MedDRA (12.0) | Systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA (12.0) | Systematic Assessment |
| |
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA (12.0) | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA (12.0) | Systematic Assessment |
| |
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA (12.0) | Systematic Assessment |
|
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Novavax Customer Service Center | Novavax Inc. | 1-844-Novavax (668-2829) | Clinicaltrials@novavax.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jan 28, 2022 | Apr 26, 2023 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D045169 | Severe Acute Respiratory Syndrome |
| D000086382 | COVID-19 |
| D018352 | Coronavirus Infections |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012140 | Respiratory Tract Diseases |
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D008171 | Lung Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000625666 | Matrix-M |
Not provided
Not provided
Not provided
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Oxford-AstraZeneca |
|
| Mixed or Other |
|
| Systemic AEs |
|
2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
| OG013 | Group P- SARS-CoV-2 rS With Matrix-M1 Adjuvant | 2 doses of Formulation 14. 1 dose each on Days 0 and Day 56. SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 5 μg SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with 50 μg Matrix-M1 Adjuvant on Days 0 and Day 56. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
| OG013 | Group P- SARS-CoV-2 rS With Matrix-M1 Adjuvant | 2 doses of Formulation 14. 1 dose each on Days 0 and Day 56. SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 5 μg SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with 50 μg Matrix-M1 Adjuvant on Days 0 and Day 56. |
|
|
2 doses of Formulation 3. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
2 doses of Formulation 3. 1 dose each on Days 0 and Day 56.
ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
2 doses of Formulation 3. 1 dose each on Days 0 and Day 56.
ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
2 doses of Formulation 3. 1 dose each on Days 0 and Day 56.
ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
2 doses of Formulation 3. 1 dose each on Days 0 and Day 56.
ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
2 doses of Formulation 3. 1 dose each on Days 0 and Day 56.
ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
2 doses of Formulation 3. 1 dose each on Days 0 and Day 56.
ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
2 doses of Formulation 3. 1 dose each on Days 0 and Day 56.
ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
2 doses of Formulation 3. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
2 doses of Formulation 3. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
2 doses of Formulation 3. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
2 doses of Formulation 3. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
2 doses of Formulation 3. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
2 doses of Formulation 3. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
2 doses of Formulation 3. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
2 doses of Formulation 3. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG002 | Group D - ICC Vaccine Formulation | 2 doses of Formulation 3. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG002 | Group D - ICC Vaccine Formulation | 2 doses of Formulation 3. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG002 | Group D - ICC Vaccine Formulation | 2 doses of Formulation 3. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| Group D - ICC Vaccine Formulation |
2 doses of Formulation 3. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| Group D - ICC Vaccine Formulation |
2 doses of Formulation 3. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG002 |
| Group D - ICC Vaccine Formulation |
2 doses of Formulation 3. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG002 |
| Group D - ICC Vaccine Formulation |
2 doses of Formulation 3. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| Group D - ICC Vaccine Formulation |
2 doses of Formulation 3. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
|
|
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
|
|
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
|
|
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
|
|
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
|
|
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
|
|
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
|
|
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| Group F- ICC Vaccine Formulation |
2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
| OG012 | SARS-CoV-2 rS With Matrix-M1 Adjuvant | 2 doses of Formulation 14. 1 dose each on Days 0 and Day 56. ... |
|
|
| Group F- ICC Vaccine Formulation |
2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
| OG012 | SARS-CoV-2 rS With Matrix-M1 Adjuvant | 2 doses of Formulation 14. 1 dose each on Days 0 and Day 56. ... |
|
|
| OG004 |
| Group F- ICC Vaccine Formulation |
2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
| OG012 | SARS-CoV-2 rS With Matrix-M1 Adjuvant | 2 doses of Formulation 14. 1 dose each on Days 0 and Day 56. ... |
|
|
| Group F- ICC Vaccine Formulation |
2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
| OG012 | SARS-CoV-2 rS With Matrix-M1 Adjuvant | 2 doses of Formulation 14. 1 dose each on Days 0 and Day 56. ... |
|
|
| Group F- ICC Vaccine Formulation |
2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
| OG012 | SARS-CoV-2 rS With Matrix-M1 Adjuvant | 2 doses of Formulation 14. 1 dose each on Days 0 and Day 56. ... |
|
|
| Group F- ICC Vaccine Formulation |
2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
| OG012 | SARS-CoV-2 rS With Matrix-M1 Adjuvant | 2 doses of Formulation 14. 1 dose each on Days 0 and Day 56. ... |
|
|
| Group F- ICC Vaccine Formulation |
2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
|
|
| Group F- ICC Vaccine Formulation |
2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG012 | Group O - qNIV With Matrix-M1 Adjuvant | 2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70. qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
|
|
| OG003 | Group E - ICC Vaccine Formulation | 2 doses of Formulation 4. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ICC Vaccine: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56. |
|
|
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
| OG012 | SARS-CoV-2 rS With Matrix-M1 Adjuvant | 2 doses of Formulation 14. 1 dose each on Days 0 and Day 56. ... |
|
|
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
| OG012 | SARS-CoV-2 rS With Matrix-M1 Adjuvant | 2 doses of Formulation 14. 1 dose each on Days 0 and Day 56. ... |
|
|
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
| OG012 | SARS-CoV-2 rS With Matrix-M1 Adjuvant | 2 doses of Formulation 14. 1 dose each on Days 0 and Day 56. ... |
|
|
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
| OG012 | SARS-CoV-2 rS With Matrix-M1 Adjuvant | 2 doses of Formulation 14. 1 dose each on Days 0 and Day 56. ... |
|
|
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
| OG012 | SARS-CoV-2 rS With Matrix-M1 Adjuvant | 2 doses of Formulation 14. 1 dose each on Days 0 and Day 56. ... |
|
|
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
| OG012 | SARS-CoV-2 rS With Matrix-M1 Adjuvant | 2 doses of Formulation 14. 1 dose each on Days 0 and Day 56. ... |
|
|
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
|
|
| OG004 | Group F- ICC Vaccine Formulation | 2 doses of Formulation 5. 1 dose each on Days 0 and Day 56. ... |
| OG005 | Group G- ICC Vaccine Formulation | 2 doses of Formulation 6. 1 dose each on Days 0 and Day 56. ... |
| OG006 | Group H and Group N- ICC Vaccine Formulation | 2 doses of Formulation 7. 1 dose each on Day 0 and Day 56. ... |
| OG007 | Group I- ICC Vaccine Formulation | 2 doses of Formulation 8. 1 dose each on Days 0 and Day 56. ... |
| OG008 | Group J -ICC Vaccine Formulation | 2 doses of Formulation 9. 1 dose each on Days 0 and Day 56. ... |
| OG009 | Group K - ICC Vaccine Formulation | 2 doses of Formulation 10. 1 dose each on Days 0 and Day 56. ... |
| OG010 | Group L - ICC Vaccine Formulation | 2 doses of Formulation 11. 1 dose each on Days 0 and Day 56. ... |
| OG011 | Group M -ICC Vaccine Formulation | 2 doses of Formulation 12. 1 dose each on Days 0 and Day 56. ... |
|
|